Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by LOUIS L PISTERS and SHI-MING TU.
LOUIS L PISTERS
Connection Strength
6.887
SHI-MING TU
  1. Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers (Basel). 2022 Jul 09; 14(14).
    View in: PubMed
    Score: 0.851
  2. Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.830
  3. Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers (Basel). 2021 Aug 09; 13(16).
    View in: PubMed
    Score: 0.798
  4. Curing Cancer: Lessons from a Prototype. Cancers (Basel). 2021 Feb 07; 13(4).
    View in: PubMed
    Score: 0.771
  5. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.550
  6. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80.
    View in: PubMed
    Score: 0.345
  7. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med. 2024 Jun 12; 13(12).
    View in: PubMed
    Score: 0.243
  8. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5).
    View in: PubMed
    Score: 0.207
  9. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14; 12(12).
    View in: PubMed
    Score: 0.191
  10. Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S56-S65.
    View in: PubMed
    Score: 0.179
  11. Rapidly enlarging abdominal mass in a patient with recurrent germ cell tumor. Clin Case Rep. 2019 Nov; 7(11):2285-2286.
    View in: PubMed
    Score: 0.176
  12. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018 10; 16(5):325-327.
    View in: PubMed
    Score: 0.160
  13. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol. 2018 05; 30(3):181-188.
    View in: PubMed
    Score: 0.159
  14. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
    View in: PubMed
    Score: 0.145
  15. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8.
    View in: PubMed
    Score: 0.124
  16. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer. 2014 Aug; 12(4):e147-50.
    View in: PubMed
    Score: 0.119
  17. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501.
    View in: PubMed
    Score: 0.094
  18. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar 15; 115(6):1310-7.
    View in: PubMed
    Score: 0.084
  19. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8.
    View in: PubMed
    Score: 0.077
  20. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec; 70(6):1173-8.
    View in: PubMed
    Score: 0.077
  21. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol. 2007 Apr; 177(4):1330-4; discussion 1334.
    View in: PubMed
    Score: 0.074
  22. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan 15; 109(2):198-204.
    View in: PubMed
    Score: 0.073
  23. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan; 177(1):131-8.
    View in: PubMed
    Score: 0.073
  24. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 01; 107(7):1483-90.
    View in: PubMed
    Score: 0.071
  25. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
    View in: PubMed
    Score: 0.053
  26. Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol. 2022 01 01; 46(1):11-17.
    View in: PubMed
    Score: 0.051
  27. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001 Aug; 166(2):521-5.
    View in: PubMed
    Score: 0.050
  28. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358.
    View in: PubMed
    Score: 0.049
  29. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306.
    View in: PubMed
    Score: 0.048
  30. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020 11 15; 126(22):4878-4885.
    View in: PubMed
    Score: 0.047
  31. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.
    View in: PubMed
    Score: 0.046
  32. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol. 2010 Jun; 41(6):832-7.
    View in: PubMed
    Score: 0.023
  33. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009 Aug; 33(8):1173-8.
    View in: PubMed
    Score: 0.022
  34. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006 Oct 01; 107(7):1503-10.
    View in: PubMed
    Score: 0.018
  35. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998 Mar; 159(3):792-5.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.